Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Healthcare
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Recent & Breaking News (NYSE:PFE)

Premier Biomedical (BIEI) and the Wild West of Modern Medicine

Accesswire April 14, 2014

Advil® Relief in Action and Josh Duhamel Celebrate National Volunteer Week with Points of Light & Kick off a Nationwide "Relief" Tour

Business Wire April 14, 2014

Pfizer's Novel CDK 4/6 Inhibitor Palbociclib plus Letrozole Significantly Prolonged Progression-Free Survival in Patients with Advanced Breast Cancer

Business Wire April 6, 2014

ViiV Healthcare announces new initiatives to improve access to dolutegravir: licence to the Medicines Patent Pool

PR Newswire April 1, 2014

Pfizer Statement on U.S. FDA Approval of Over-the-Counter Nexium® 24HR

Business Wire March 28, 2014

In A Subanalysis, The Benefits Of Eliquis® (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood Pressure Control 1

Business Wire March 27, 2014

Bococizumab (RN316) Significantly Reduced LDL Cholesterol In Statin-Treated Adults With High Cholesterol In A Phase 2b Study1

Business Wire March 27, 2014

Pfizer Achieves Primary Endpoint With Phase 3B Top-Line Results Of GENOTROPIN® In Very Young Children Born Small For Gestational Age

Business Wire March 26, 2014

Pfizer Invites Public To View And Listen To Webcast Of May 5 Conference Call With Analysts

Business Wire March 25, 2014

Pfizer Reports Positive Phase 3 Study Outcome Of XALKORI® (crizotinib) Compared To Chemotherapy In Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Business Wire March 25, 2014

Apply Market Savvy to Bear Market Debris; Uncover Biotech Treasures: Cleland and Ireland

Equities.com March 24, 2014

A.M. Best Affirms Ratings of Blue Whale Re Ltd.

Business Wire March 24, 2014

Pfizer Announces Detailed Results of OPT Compare Phase 3 Study of Tofacitinib 5 mg and 10 mg Twice Daily Compared to High-Dose ENBREL® in Adults with Moderate-to-Severe Chronic Plaque Psoriasis

Business Wire March 22, 2014

Pfizer's Investigational Vaccine Candidate Bivalent rLP2086 Receives U.S. Food and Drug Administration Breakthrough Therapy Designation for Potential Prevention of Meningococcal B Disease

Business Wire March 20, 2014

Promising Biotechs Target New Ways to Kill Bad Bugs: Venture Capitalist Dennis Purcell

Equities.com March 19, 2014

ViiV Healthcare Announces Next Round of the Positive Action Southern Initiative to Support Linkages to HIV/AIDS Care and Treatment Adherence

PR Newswire March 19, 2014

Pfizer Launches 2013 Integrated Annual Review

Business Wire March 18, 2014

U.S. FDA Approves Eliquis® (apixaban) To Reduce The Risk Of Blood Clots Following Hip Or Knee Replacement Surgery

Business Wire March 14, 2014

Pfizer Will Appeal Court Decision Regarding Celebrex Reissue Patent

Business Wire March 12, 2014

Pfizer Announces Webcast Of April 6 Conference Call With Securities Analysts To Review Palbociclib Phase 2 Final Results Following Presentation At AACR Annual Meeting 2014

Business Wire March 12, 2014